Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:ATAI News 18 October 2025

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Psychedelic Biotech Rally: Atai Life Sciences Stock Soars 18% on FDA Breakthrough and $130M Fundraise

Stock Surge & Analyst Reaction Atai shares exploded higher on Oct. 17, 2025. Investors bid the stock up ~17.7%, closing at roughly $6.45 ts2.tech (versus ~$5.48 offering price). In after-hours trading it briefly touched ~$6.86 ts2.tech. This rally follows a week of good news: BPL-003’s FDA breakthrough, plus well-received capital raise plans. Volume on Oct. 17 was very high (tens of millions of shares), reflecting heavy trading. Over 2025 the stock has skyrocketed ~348% ts2.tech, making ATAI one of the year’s top biotech performers. Its market cap now hovers around $1.2 billion ts2.tech. Analysts have taken notice. Needham Research just initiated
18 October 2025
·
ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

ATAI Life Sciences Skyrockets on FDA Breakthrough and $130M Cash Infusion

Key Facts – October 18, 2025 Stock Soars on Breakthrough News and Funding Boost ATAI’s stock price surged in the last few days amid a flurry of good news. Shares jumped 17.7% on Friday (Oct 17) alone, finishing at $6.45marketbeat.com, after trading around the mid-$5 range earlier in the week. In fact, as of early Friday, ATAI was already up about 8% for the week on anticipation of the announcementsnasdaq.com. The strong finish came as investors digested multiple catalysts: a coveted FDA designation for a key drug, a fresh capital raise, and bullish commentary from analysts. Notably, after-hours trading on
18 October 2025
·

Stock Market Today

Idox share price stuck below 71.5p bid as Long Path says backing nears control

Idox share price stuck below 71.5p bid as Long Path says backing nears control

8 February 2026
Long Path Partners said it has aggregate support for about 49.26% of Idox shares for its 71.5p-per-share cash offer. Idox shares closed Friday at 71.0p, about 0.7% below the offer price. Valid acceptances stood at 19.12% as of Feb. 5, with the offer open until March 16. The deal requires more than 50% of voting rights to go unconditional.
BAE Systems share price: Buyback update and Launchpad incubator set up Feb 18 results

BAE Systems share price: Buyback update and Launchpad incubator set up Feb 18 results

8 February 2026
BAE Systems shares closed up 1.2% at 1,879 pence on Friday, with 5.6 million shares traded. The company disclosed buying back 115,039 shares for cancellation at a volume-weighted average price of 1,860.32 pence. Over 1,200 BAE workers in northwest England are striking over pay until at least Feb. 20. Full-year results are due Feb. 18.
Barclays share price jumps into earnings week: what to watch before Tuesday’s results

Barclays share price jumps into earnings week: what to watch before Tuesday’s results

8 February 2026
Barclays shares closed up 2.71% at 479.1 pence on Friday, ahead of full-year results and a targets update due Tuesday. Barclays and NatWest have both submitted offers for Evelyn Partners, with a deal announcement possible this week, according to Reuters. Mary Francis will retire from the Barclays board in May. Investors are watching for signals on costs, credit quality, and capital returns.
Rolls-Royce share price ends week higher on buyback update as RR.L eyes turn to results

Rolls-Royce share price ends week higher on buyback update as RR.L eyes turn to results

8 February 2026
Rolls-Royce Holdings shares closed at 1,229p on Friday, up 1.78%, as the FTSE 100 gained 0.59%. The company reported buying 742,570 shares on Feb. 5 as part of its £200 million buyback, bringing total repurchases to 12.66 million shares. Rolls-Royce will attend the World Defense Show in Riyadh, noting over 80% of its Saudi workforce are nationals.
Go toTop